ライフサイエンスコーパス: pretransplant

1 to both HLA and non-HLA antigens are present pretransplant.

2 d BKV in oral washes, urine, and whole blood pretransplant.

3 occurred more frequently in patients with a pretransplant ABO antibody titre higher than 16 and/or p

4 terferon, limited in efficacy, restricted to pretransplant administration because of concerns related

5 Pretransplant admission strongly predicted more frequent

6 ry model for end-stage liver disease scores, pretransplant alpha fetoprotein, and cumulative tumor di

7 ken in parallel with HLA antibody assessment pretransplant and 1-3 months posttransplant.

8 Sera were collected pretransplant and at 3 monthly intervals up to 5 years p

9 four patients had at least two serum samples pretransplant and at least two samples posttransplant.

10 nts underwent HLA-antibody testing quarterly pretransplant and at regular intervals over the first 24

11 ositron emission tomography (PET) positivity pretransplant and detectable minimal residual disease (M

12 Pretransplant and intraoperative bariatric surgeries hav

13 nts in multivariate analysis controlling for pretransplant and pathologic factors (HR 1.32, P = 0.044

14 387 were transplanted, and 326 provided both pretransplant and post-transplant data.

15 galovirus (CMV) activity was assessed in 280 pretransplant and posttransplant blood samples from 33 d

16 to determine the type of organ transplanted, pretransplant and posttransplant cancer, and immunosuppr

17 allocation, adherence to prescribed therapy, pretransplant and posttransplant care, implementation of

18 Associations with pretransplant and posttransplant delisting/mortality, ho

19 l practice are associated with reductions in pretransplant and posttransplant hyperparathyroidism, vi

20 al confounding variables identified separate pretransplant and posttransplant IR thresholds for predi

21 Pretransplant and posttransplant management is essential

22 B) are used for monitoring HLA antibodies in pretransplant and posttransplant patients despite the di

23 Pretransplant and posttransplant sera from 162 lung reci

24 Pretransplant and posttransplant sera from 200 recipient

25 The probabilities of pretransplant and posttransplant survival, progression o

26 sensitive to varying the probability of both pretransplant and posttransplant survival.

27 ted data on the tolerability of LTBI therapy pretransplant and posttransplant.

28 Pretransplant and technical variables were included in t

29 longer duration of renal replacement therapy pretransplant and the occurrence of leukopenia were risk

30 graphic progression of CAD between baseline (pretransplant) and follow-up at 7 years or older.

31 with >/=0.1% minimal residual disease (MRD) pretransplant, and decreased risk in patients with grade

32 xyurea and azathioprine starting at -45 days pretransplant, and fludarabine from days -16 to -12.

33 We examined the prevalence of pretransplant anti-HLA antibodies at varying thresholds

34 Ninety percent of the patients with pretransplant anti-HLA antibodies had class I antibodies

35 Characteristics of pretransplant antibodies directed at donor human leukocy

36 rejection were observed for recipients with pretransplant antibodies to AT1R (P = 0.19) and ETAR (P

37 When the pretransplant antibody status of HLA-specific antibody (

38 ents achieving a positive value (mean+2SD of pretransplant antibody titers) of IgM AVA (50% versus 37

39 Median duration of pretransplant antifungal therapy and posttransplant ther

40 Short-term pretransplant antiviral therapy is a feasible strategy i

41 Pretransplant antiviral therapy to eradicate HCV reduces

42 A careful oncological surveillance pretransplant as well as posttransplant is recommended.

43 Pretransplant Aspergillus colonization is frequent among

44 This study evaluated the impact of pretransplant Aspergillus colonization on the risk for I

45 tion were reviewed to identify patients with pretransplant Aspergillus colonization.

46 Seventy percent (65/93) of CF-LTRs had pretransplant Aspergillus colonization.

47 ansplant (simultaneous), and recipients with pretransplant bilateral nephrectomies (pre).

48 The role of pretransplant biopsy in defining the quality of kidney g

49 is study was to investigate the influence of pretransplant biopsy score on long-term graft outcome.

50 ors between 1997 and 2007, with an available pretransplant biopsy.

51 We retrospectively determined the pretransplant BKV neutralizing serostatus of 116 donors

52 s a graded, detrimental impact of increasing pretransplant BMI on the risk of graft failure after kid

53 The impact of pretransplant body mass index (BMI) on long-term allogra

54 To evaluate the effect of pretransplant bridging locoregional therapy (LRT) on hep

55 Each patient had a separate donor; however, pretransplant bronchoalveolar lavage fluid was only avai

56 The patient was JCPyV naive pretransplant, but showed high antibody titers during th

57 to assess whether modifying muscle function pretransplant can lead to improved clinical outcomes.

58 ll (n = 95) renal transplanted patients with pretransplant cancer diagnoses in the Uppsala-Orebro reg

59 Kidney transplant recipients with a pretransplant cancer had a similar overall patient and g

60 Patients with pretransplant cancer showed higher incidence of posttran

61 atient and graft survival of recipients with pretransplant cancer to the outcomes of matched recipien

62 istry and included European patients without pretransplant cancer.

63 to 2010, 377 (6.4%) of 5867 recipients had a pretransplant cancer.

64 on coronary artery disease, a comprehensive pretransplant cardiac evaluation must consider other pro

65 n obese individuals and remain the basis for pretransplant cardiovascular evaluation and risk stratif

66 ct plan was estimated to reduce payments for pretransplant care ($1638 million to $1506 million, p <

67 Importantly, pretransplant CD antigen expression is most predictive o

68 ncerning HSCT itself (including the need for pretransplant chemotherapy, the best conditioning regime

69 In a subset of 37 recipients, pretransplant circulating Treg cell-suppressive function

70 ficantly associated with presentation to the pretransplant clinic before initiation of dialysis.

71 , screening instruments, clinical monitoring pretransplant, clinical monitoring posttransplant, patie

72 Pretransplant CMV serology is currently the only tool fo

73 pothesized that a more precise evaluation of pretransplant CMV-specific immune-sensitization using th

74 Nineteen (28%) of 67 D+R- KTRs showed pretransplant CMV-specific T cells.

75 undred sixty-two (80%) of 203 R+ KTRs showed pretransplant CMV-specific T cells.

76 has been reported in 13% to 50% of selected pretransplant cohorts, but use of more precise diagnosti

77 Thus, pretransplant comorbidities are associated with the deve

78 Nine pretransplant comorbidity covariates were defined: cardi

79 ith early hospital readmission often reflect pretransplant comorbidity, and many of these factors may

80 Thus, myeloablative pretransplant conditioning can be safely combined with h

81 Pretransplant conditioning consisted of fludarabine and

82 ransplantation (ABOi) in children is rare as pretransplant conditioning remains challenging and conce

83 In conclusion, pretransplant COPD, impaired graft function and the occu

84 from January 1996 through November 2010 with pretransplant coronary angiogram were included in our st

85 bar lung transplants and those who underwent pretransplant coronary revascularization were excluded.

86 Pretransplant counseling and posttransplant tailored imm

87 enal transplant recipients and donors during pretransplant counselling.

88 no significant differences in transplant and pretransplant covariates between induction and no induct

89 Pretransplant creatinine was consistently a statisticall

90 ghly optimized for favorable outcomes in the pretransplant DAA treatment arm (low availability of HCV

91 The pretransplant DAA treatment strategy trended towards cos

92 lth outcomes at cost savings compared to the pretransplant DAA treatment strategy.

93 We compared pretransplant DAA treatment versus deferred DAA treatmen

94 CI, 1.18-4.10, P=0.01) after adjustment for pretransplant/de novo donor-specific antibody and delaye

95 dementia and AD were older recipient age and pretransplant diabetes.

96 Pretransplant diagnosis of chronic pulmonary obstructive

97 index, mean pulmonary arterial pressure, and pretransplant diagnosis, higher E/e and E/e greater than

98 If the pretransplant dialysis duration is extended to 12 weeks,

99 When 1-week pretransplant dialysis duration is required, the numbers

100 We studied the association of pretransplant dialysis duration on outcomes after kidney

101 The association of pretransplant dialysis duration with the risk of specifi

102 Multivariate predictors of RAF included pretransplant dialysis duration, kidney cold ischemia, k

103 Adjustments for pretransplant dialysis duration, sex, country, and trans

104 Although longer pretransplant dialysis has been associated with poor kid

105 and graft survival were compared for preKT, pretransplant dialysis less than 1 year, and pretranspla

106 ic time, donor age, previous transplant, and pretransplant dialysis modality.

107 pretransplant dialysis less than 1 year, and pretransplant dialysis recipients of 1 year or longer.

108 Longer duration of pretransplant dialysis was an independent risk factor fo

109 The association of the duration of pretransplant dialysis with patient and graft survival a

110 ive excellent-quality kidneys, but most need pretransplant dialysis.

111 d in patients with greater than 12 months of pretransplant dialysis.

112 Neither pretransplant disorder was related to risk for any outco

113 Pretransplant DNA samples from 696 CBUs with malignant d

114 an adequately powered study to determine if pretransplant donor treatment with valG can reduce postt

115 trolled trial, we studied whether 14 days of pretransplant donor treatment with valganciclovir (valG)

116 Sensitized recipients with pretransplant donor-specific Abs are at higher risk for

117 chimeric subjects were nearly as diverse as pretransplant donors and recipients, and were comparable

118 gy (median time after transplant, 5.0 years; pretransplant DSA documented in 19 recipients), who were

119 The incidence of strong pretransplant DSA that persist after transplantation was

120 Pretransplant DSA was detected in 12 (11%) recipients wi

121 antibody-mediated rejection in patients with pretransplant DSA, neither the presence of HLA antibodie

122 vival longer than 1 year, and (3) absence of pretransplant DSA.

123 ansplant cardiac events in the subgroup with pretransplant electrocardiogram and echocardiogram (n=16

124 f PET/CT imaging for response assessment and pretransplant evaluation in lymphoma.

125 and recommendations for LT with indications, pretransplant evaluation, and posttransplant management.

126 especially among patients with a history of pretransplant exposure to alloantigens, to predict subse

127 There were no associations between pretransplant features and 3-month overall HY-Ab develop

128 ery year after transplantation compared with pretransplant for both IFTA and controls groups (P<0.001

129 ry and prosurvival abilities, as a means for pretransplant gene therapy.

130 Thirteen of the 22 patients in the pretransplant group who required 7 or more days of CRRT

131 in the general surgical group and 55 in the pretransplant group.

132 At 3 months, patients who used midodrine pretransplant had significantly (P < 0.05) higher rates

133 s higher in patients with higher proteinuria pretransplant [hazard ratio = 1.869 (95% confidence inte

134 in kidney allograft recipients with negative pretransplant HBc, HCV, EBV, or CMV serology.

135 ch is necessary for those patients with high pretransplant HBV DNA levels, those with limited antivir

136 and hepatitis D virus-negative patients with pretransplant HBV DNA undetectable to 100 IU/mL who rece

137 ality were male gender (HR 2.40, P = 0.001), pretransplant hepatocellular (HR 2.92, P = 0.001) or bil

138 For pretransplant HHV8 screening in both donors and recipien

139 Our data suggest that 1) pretransplant histological score may predict long-term g

140 In a multivariate logistic regression, pretransplant histological score was independently assoc

141 In a multivariate Cox model, only pretransplant histological score was significantly assoc

142 Pretransplant HIV viral load was undetectable (<50 copie

143 s of activated naive B cells are linked with pretransplant HLA immunization and the development of po

144 , including method of allograft preservation pretransplant, HLA matching, and calculated KDRI.

145 times (270 days vs 186 days, P < 0.001), and pretransplant hospital stays (10 days vs 8 days, P < 0.0

146 e scores (33 vs 27; P < .001); more frequent pretransplant hospitalization (72.0% vs 47.9%; P < .001)

147 Pretransplant HRS2 is associated with early posttranspla

148 On multivariate analysis, pretransplant HRS2 was associated with CKD3 at 3 (odds r

149 We investigated whether pretransplant identification of patients with CAD is hel

150 In conclusion, pretransplant IgA-aB2GP1 was the main risk factor for gr

151 In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early gr

152 Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effec

153 The median number of pretransplant immunoadsorptions was 5.

154 The desensitization protocol involved pretransplant immunosuppression, plasmapheresis, and low

155 nses to IE-1 antigen were practically absent pretransplant in patients who developed CMV infection po

156 A pretransplant infection by a resistant pathogen was sign

157 ore to predict posttransplant outcomes using pretransplant information including routine laboratory d

158 Pretransplant, intraoperative, and posttransplant variab

159 Pretransplant leukocyte telomere length in the recipient

160 r increase in donor-specific antibodies from pretransplant levels are associated with adverse outcome

161 Neither >/= 17 nor >/= 12 units of pretransplant levels indicated a significant difference

162 ividual's immune system and that recovery of pretransplant levels of catalytic IgG is accompanied by

163 The mean pretransplant levels of IgG AVA in the IFTA and control

164 nt viremia was reduced among cases with high pretransplant levels of NKG2C(+) NK cells.

165 were enrolled into 2 strata defined by their pretransplant levels of parathyroid hormone (PTH), low P

166 ABO nonidentical patients (n = 58), provided pretransplant levels of relevant isoagglutinins were bel

167 Lower pretransplant life expectancy (need) was more important

168 sttransplant life expectancy; 1 year less of pretransplant life expectancy required an increase of 1.

169 Pretransplant life expectancy was valued more highly tha

170 Pretransplant liver biopsies were analyzed by immunostai

171 Pretransplant LRT mitigates these risks by inducing tumo

172 Furthermore, severe pretransplant lymphopenia (<500/muL) was an independent

173 Pretransplant machine perfusion of DCD kidneys (vs. stat

174 al study to analyze the relationship between pretransplant magnesemia (Mg) and the risk of NODAT with

175 conducted to determine the risk conferred by pretransplant magnesium level on development of NODAT wi

176 1, 1991, and October 20, 2014, and who had a pretransplant magnetic resonance imaging (MRI) severity

177 id organ transplant recipients (SOTR) with a pretransplant malignancy (PTM) are at increased risk for

178 Pretransplant malignancy increased the risk of posttrans

179 Our study objective is to identify whether pretransplant malignancy increases the risk for posttran

180 Pretransplant malignancy is associated with increased ri

181 A history of any pretransplant malignancy was associated with increased r

182 tified according to the presence and type of pretransplant malignancy.

183 nancy risk differed according to the type of pretransplant malignancy.

184 1.05-1.30) when compared with those without pretransplant malignancy.

185 he risk remained elevated when patients with pretransplant malignant neoplasms (n = 1124) were exclud

186 ment of IE-1-specific CD8 T-cell frequencies pretransplant may be a useful tool for identifying serop

187 There was a significant increase between the pretransplant mean levels of IgG AVA and the levels at y

188 from the EDSS improved significantly from a pretransplant median of 4.0 to 3.0 (interquartile range

189 The NRS scores improved significantly from a pretransplant median of 74 to 88.0 (IQR, 77.3 to 93.0; n

190 re was a decrease in T2 lesion volume from a pretransplant median of 8.57 cm3 (IQR, 2.78 to 22.08 cm3

191 A history of pretransplant melanoma, previous kidney transplantation,

192 ce was found in 2 of 7 patients with HBL and pretransplant metastases, which were not found to be an

193 NODAT patients had lower levels of pretransplant Mg as compared with non-NODAT patients (P<

194 This study supports that a low pretransplant Mg level is an independent risk factor of

195 adjustment to several variables demonstrated pretransplant Mg to be an independent risk factor of NOD

196 as for the propensity of midodrine exposure, pretransplant midodrine use was independently associated

197 Adjusted associations of pretransplant midodrine use with complications at 3 and

198 or HCV-Donor Risk Index, warm ischemic time, pretransplant Model for Endstage Liver Disease (MELD) an

199 Patients were screened for DSA pretransplant, monitored regularly posttransplant and wh

200 ars), there was a significant association of pretransplant MRI severity and baseline verbal comprehen

201 Higher pretransplant MRI severity scores were also associated w

202 y the end of the experiment, although early (pretransplant) negative effects of pCO2 on recruitment o

203 Luminex Single Antigen Flow Bead assays, 346 pretransplant nonsensitized kidney recipients were scree

204 t-transplant health states (HRQL better than pretransplant, not better, or dead) and estimated qualit

205 of dominant populations present in patients pretransplant, notably Pseudomonas in individuals with c

206 Studies addressing pretransplant nutritional interventions to reduce AML re

207 Epstein-Barr virus (EBV) seronegative status pretransplant (odds ratio [OR] = 7.61, 95% confidence in

208 Graded associations of pretransplant opioid exposure level with death and graft

209 ging concepts include the use of ruxolitinib pretransplant, optimizing MAC to decrease toxicity, and

210 such that most patients can be cured in the pretransplant or posttransplant setting.

211 Recent results using ex situ pretransplant organ perfusion of DCD organs has been enc

212 High levels of pretransplant panel reactive antibodies (PRA) are known

213 We found no significant difference in pretransplant panel reactive antibodies, acute rejection

214 were always significantly lower than in the pretransplant period.

215 howed that >16 HLA-DQ epitope mismatches and pretransplant, peripheral blood, donor-reactive IFN-gamm

216 selected recipients with 1 year of captured pretransplant pharmaceutical fill records (N=31,197).

217 Pretransplant pharmacokinetic testing was performed to d

218 The pretransplant population was censored from further survi

219 graft outcomes, but the association between pretransplant PRA levels and long-term patient outcomes

220 8-1.0), low CD8 responses to IE-1 (</=0.05%) pretransplant predicted the development of CMV infection

221 Therefore, pretransplant predictive markers are needed.

222 frequency of antibody-mediated rejection and pretransplant proportion of any B-cell subset or BAFF se

223 hematological malignancy, and had available pretransplant pulmonary function test results.

224 sttransplant QOL was valued more highly than pretransplant QOL.

225 Pretransplant QT-time corrected by heart rate (QTc) and

226 Ten of 15 patients who started the pretransplant rapamycin treatment completed it.

227 nsplant or major abdominal operation, longer pretransplant recipient and donor length of stay, greate

228 Pretransplant recipient circulating CD4+CD127lo/-TNFR2+

229 this prospective observational cohort study, pretransplant recipient circulating CD4+CD25+CD127lo/- a

230 mpler alternative to Treg cell function as a pretransplant recipient immune marker for AKI (DGF + SGF

231 otein at recurrence, donor serum sodium, and pretransplant recipient neutrophil-lymphocyte ratio.

232 There were no differences in the pretransplant recipient or donor characteristics apart f

233 s who displayed high levels of catalytic IgG pretransplant recovered high levels of catalytic Abs 2 y

234 Both donors had renal failure and pretransplant renal biopsies showing 100% of the glomeru

235 The severity and duration of pretransplant renal dysfunction, hepatitis c, diabetes,

236 to investigate potential association between pretransplant renal function impairment and cardiac even

237 Pretransplant renal impairment is a predictor of cardiac

238 In Cox regression analysis, pretransplant renal impairment was found to be an indepe

239 alized (50% vs 47%, P = 0.026) and receiving pretransplant renal replacement therapy (34% vs 12%, P <

240 and are widely used in organ allocation and pretransplant risk assessment.

241 at an increased cardiovascular risk, had no pretransplant risk factors, were aged 60 years and older

242 The response was analyzed in pretransplant samples and prospectively at 1 and 6 month

243 ntigens were differentially expressed on the pretransplant samples compared to any posttransplant tim

244 A pretransplant score comprising renal impairment, prolong

245 hat warrants attention in efforts to improve pretransplant screening and management protocols before

246 We performed serological and molecular pretransplant screening in solid organ transplant (SOT)

247 e studies are needed to define the impact of pretransplant sensitization on lung transplant recipient

248 odified immunosuppression depending on their pretransplant sensitization status.

249 Cardiac risk, pretransplant septic shock, and comorbidities are the mo

250 MELD score, pretransplant septic shock, cardiac risk, and comorbidit

251 We prospectively screened pretransplant sera from 543 kidney recipients using sing

252 All four AECAs were detected in 24% of pretransplant sera, and they were associated with post-t

253 Weight loss coincided with reduced pretransplant serum leptin levels.

254 Low pretransplant serum testosterone has recently been assoc

255 Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively.

256 JC polyomavirus was not detected in pretransplant serum, however viral loads increased with

257 Hypomethylating agents are effective in the pretransplant setting to reduce disease burden.

258 tors for posttransplant skin cancer included pretransplant skin cancer (HR, 4.69; 95% CI, 3.26-6.73),

259 index posttransplant cancer were history of pretransplant skin cancer (subhazard ratio, 2.1; 95% CI,

260 , death and graft failure in recipients with pretransplant skin cancer compared with those without ca

261 Recipients with pretransplant skin cancer had increased risk of PTM (sub

262 idence of PTM in patients with and without a pretransplant skin cancer history was 31.6% and 7.4%, re

263 Pretransplant skin cancer was associated with an increas

264 We studied the association between pretransplant skin cancer, PTM, death, and graft failure

265 Pretransplant skin malignancy increased the risk of post

266 ded 1671 recipients with and 102 961 without pretransplant skin malignancy.

267 Pretransplant solid malignancy also increased the risk o

268 atistically significant differences included pretransplant support (25.6% mechanical circulatory supp

269 Patients were categorized by their type of pretransplant support: no support, ECMO only, invasive m

270 tigated a conditioning regimen consisting of pretransplant T cell depletion, low-dose total body irra

271 Lower pretransplant testosterone was associated with lower rej

272 vers necessitate the development of accurate pretransplant tests of viability.

273 lant irrespective of their MELD meaning that pretransplant therapy cannot reduce costs in such settin

274 t state of LT recipients, identified through pretransplant thromboelastographic (TEG) data among othe

275 ate the evolution of mineral metabolism from pretransplant through the first year after transplantati

276 Patients with pretransplant titers of 1 or more in 8 received rituxima

277 mproved from a mean of 46 (95% CI, 43 to 49) pretransplant to 64 (95% CI, 61 to 68) at a median follo

278 rved for recipients with antibodies detected pretransplant to AT1R (P = 0.054), ETAR (P = 0.012), and

279 xic and immunosuppressive drugs administered pretransplant to eliminate the host hematopoietic/immune

280 raining samples and IR of 1.23 or greater in pretransplant training samples predicted LTx or ITx reje

281 hlight the various issues to consider in the pretransplant, transplant and posttransplant periods wit

282 ymphocyte, CD19(+), and NK-cell numbers from pretransplant until 15 years posttransplant.

283 Pretransplant urinary BKV shedding of donor and recipien

284 Pretransplant urinary BKV shedding of donor or recipient

285 entiated memory T cells/muL rejected, median pretransplant values of the biomarkers did not differ be

286 his study was to evaluate the association of pretransplant variables with mortality within 90 days fo

287 (median [min-max] 71.2 muM [29.2-189.7 muM] pretransplant versus 11.4 muM [8.9-20.2 muM] post-transp

288 Pretransplant viremia (odds ratio, 11.3; P < .01), acute

289 A similar impact of pretransplant VitD deficiency on relapse risk in myeloid

290 Conclusion Pretransplant VitD deficiency was associated with a high

291 A significant association of pretransplant VitD deficiency with higher relapse rates

292 Patients and Methods The impact of pretransplant VitD status on overall survival, relapse m

293 Overall response rate pretransplant was 97%.

294 Pretransplant weight loss along with serum levels of tot

295 This study investigates the influence of pretransplant weight loss and serologic indicators of nu

296 We identified pretransplant weight loss and TSP as strong independent

297 M was 3 hours shorter than those requiring a pretransplant XM (P < 0.0001).

298 XM) (P < 0.0001), and use of donor blood for pretransplant XM (P < 0.0001).

299 ng transplants despite organ, recipient, and pretransplant XM result being ready, suggesting that the

300 , 1 to 7, 8 to 14, or 15 or more days in the pretransplant year were 51%, 25%, 11%, and 13%.